secwatch.observer — SEC 8-K summary
======================================

Issuer:     LivaNova PLC (LIVN)
CIK:        0001639691
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001639691-25-000146
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

LivaNova Q3 revenue $357.8M (+12.5% organic); raises FY2025 EPS guidance to $3.80-$3.90
--------------------------------------------------------------------------------

- Third-quarter revenue $357.8M, up 12.5% reported, 11% constant-currency, and 12.5% organic vs prior year.
- GAAP diluted EPS $0.49; adjusted diluted EPS $1.11.
- Raised FY2025 guidance: revenue growth 8.5%-9.5% constant currency, EPS $3.80-$3.90, FCF $160M-$180M.
- Initiated commercial launch of Essenz Perfusion System in China, the second-largest heart-lung machine market.
- Appointed Donald Zurbay to the Board of Directors and Audit and Compliance Committee.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/0001639691-25-000146-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1639691/000163969125000146/livn-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001639691-25-000146

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer